Nature Reviews Drug Discovery contents December 2011 Volume 10 Number 12 pp 881-963

Advertisement
Your mission: Conquering cancer. Our mission: Providing the tools. Oncology researchers look to Taconic for the tools they need to advance their research. These tools include one of the industry's broadest, deepest portfolios of xenograft models for immediate delivery, as well as products like the Pirc rat for colon cancer and the CIEA NOG mouse® for humanization studies.
TABLE OF CONTENTS
December 2011 Volume 10 Number 12		Advertisement
Impact Factor 28.712 * Subscribe to Nature Reviews Drug Discovery Recommend to your library	In this issue News and Analysis Research Highlights Reviews Correspondence Also this month  Featured article: Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets Joon-Il Jun & Lester F. Lau	RNA-Seq just went from complicated to compatible. EA will provide your data in a format you are used to -- 100% microarray compatible format. Now you can have your data and use it too! Expression Analysis will help you detect 2x more differentially expressed transcripts, novel isoforms and SNVs and can achieve >97% alignment to your reference genome. 919-405-2248
Advertisement
BioPharma Dealmakers Science, strategy & innovation Recent content exclusively made freely available to you from Nature Biotechnology, Nature Reviews Drug Discovery and Nature Medicine Produced with support from TVG Sign up to receive this new bi-weekly newsletter today.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
SciBX: Science - Business eXchange from NPG and BioCentury Joining the scientific acumen of NPG and the business intelligence of BioCentury to evaluate new developments in life science and technology that have commercial and investment potential for the pharmaceutical and biotechnology industries. Visit www.SciBX.com to reserve your copy of this new weekly groundbreaking publication today.
In this issue p881 | doi:10.1038/nrd3601 Full Text
Editorial: Expanding precompetitive space p883 | doi:10.1038/nrd3602 Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Success of immunomodulators in MS shifts discovery focus to neuroprotection Asher Mullard p885 | doi:10.1038/nrd3610 With six immunomodulatory agents in late-stage development for relapsing-remitting multiple sclerosis, this area of the therapeutic space has become highly competitive. Could remyelination therapies that provide neuroprotection be the next frontier? PDF
Quarter-century quest for malaria vaccine shows signs of success Alisa Opar 887 | doi:10.1038/nrd3611 The long development of RTS,S, the leading malaria vaccine candidate, has yielded preliminary positive Phase III results, and laid a path for future success. PDF
NEWS IN BRIEF End of the Lipitor era | Moving towards quantitative and systems pharmacology | AstraZeneca/Targacept's antidepressant fails in first Phase III trial p889 | doi:10.1038/nrd3609 PDF
BIOBUSINESS BRIEFS Deal watch: MicroRNA collaboration to target cardiovascular disease pathways p890 | doi:10.1038/nrd3621 PDF
Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs p890 | doi:10.1038/nrd3622 PDF
Trial watch: An all-oral and interferon-free future for HCV therapy? p891 | doi:10.1038/nrd3623 PDF
PATENT WATCH EU bans embryonic stem cell patents but decision may have limited implications Charlotte Harrison p892 | doi:10.1038/nrd3612 PDF
AN AUDIENCE WITH Marc Kirschner p894 | doi:10.1038/nrd3613 Marc Kirschner, Chairman of Harvard Medical School's Department of Systems Biology, discusses Harvard's new Initiative in Systems Pharmacology. PDF
FROM THE ANALYST'S COUCH Personalized medicine in oncology: next generation Alex Chiang & Ryan P. Million p895 | doi:10.1038/nrd3603 PDF
FRESH FROM THE PIPELINE Crizotinib Alice T. Shaw, Uma Yasothan & Peter Kirkpatrick p897 | doi:10.1038/nrd3600 PDF
RESEARCH HIGHLIGHTS Top Cardiovascular disorders: microRNA modulation elevates HDL p899 | doi:10.1038/nrd3605 PDF Analgesia: Unravelling epigenetic mechanisms of chronic pain p900 | doi:10.1038/nrd3606 PDF Antisense therapeutics: Systemic reawakening of a silent gene to improve survival in SMA p900 | doi:10.1038/nrd3608 PDF Neurodegenerative diseases: An alternative path to reduce neuroinflammation p901 | doi:10.1038/nrd3607 PDF Medical devices: A protective stent coating p902 | doi:10.1038/nrd3604 PDF IN BRIEF Antibacterial drugs: Parallel pathways of kanamycin biosynthesis | Cancer: Targeting cytomegalovirus fights medulloblastoma | Obesity and diabetes: A novel way of inhibiting a protein tyrosine phosphatase | Anticancer drugs: Redirecting alternative splicing PDF Drug Discovery JOBS of the week Professor, Associate Professor, or Assistant Professor Columbia University Herchel Smith Postdoctoral Research Fellowships - Biological Sciences University of Cambridge W3-Professur fur Unfallchirurgie Medizinischen Fakultat Heidelberg Scientific Positions Institute of Microbial Technology Dr. Josef Steiner Cancer Research Award 2013 Dr. Josef Steiner Cancer Foundation More Science jobs from Drug Discovery EVENT Advances and Progress in Drug Design 21.-22.02.11 London, UK More science events from
Advertisement
Whole genome interpretation service for investigating drug response knomeDISCOVERY is a complete genome interpretation service for researchers investigating the genetic basis of drug response. It includes whole genome sequencing, project-driven curation, and short-listing of suspect variants, genes, and gene networks. $4,998 per genome. Learn more.
REVIEWS		Top
Exploring HCN channels as novel drug targets Otilia Postea & Martin Biel p903 | doi:10.1038/nrd3576 Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are known for their role in controlling the rhythmic activity of cardiac pacemaker cells and spontaneously firing neurons. They are now emerging as interesting targets not only for the development of drugs to lower heart rate but also for the treatment of diseases related to impaired neuronal activity, such as epilepsy and neuropathic pain. Abstract | Full Text | PDF
Induced pluripotent stem cells — opportunities for disease modelling and drug discovery Marica Grskovic, Ashkan Javaherian, Berta Strulovici & George Q. Daley p915 | doi:10.1038/nrd3577 Induced pluripotent stem cells (iPSCs) – whereby a patient's somatic cells are reprogrammed into an embryonic pluripotent state by the forced expression of a defined set of transcription factors – have the potential to transform drug discovery and development. In this article, Daley and colleagues discuss recent advances and current challenges associated with the generation and use of iPSCs. Abstract | Full Text | PDF
Advertisement
TALEN® Sure KO™: knock-out any gene within the 1st coding exon Our recently launched and very affordable TALEN® Sure KO™ service enables sure gene knock-out by introducing a frame shift within the first coding exon of any gene. TALENs® are next generation genome customization tools to knock-out genes or introduce modifications in any gene, at any position, in any genome.
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases Daniel W. Neef, Alex M. Jaeger & Dennis J. Thiele p930 | doi:10.1038/nrd3453 Neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease are associated with the accumulation of misfolded proteins, resulting in neuronal dysfunction and cell death. Thiele and colleagues discuss the therapeutic potential of combating protein misfolding by harnessing the natural cellular protein-folding machinery through pharmacological activation of heat shock transcription factor 1, the master regulator of chaperone protein expression. Abstract | Full Text | PDF
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets Joon-Il Jun & Lester F. Lau p945 | doi:10.1038/nrd3599 Here, the authors discuss how aberrant expression and activity of the CCN matricellular proteins contribute to the pathobiology of diseases linked to inflammation or chronic tissue injury, and they highlight how these proteins could be potential therapeutic targets. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Lessons from 54 years of pharmaceutical research Raymond A. Firestone p963 | doi:10.1038/nrd2961-c1 Full Text | PDF
Erratum: Perspectives and opportunities for nanomedicine in the management of atherosclerosis Mark E. Lobatto, Valentin Fuster, Zahi A. Fayad & Willem J. M. Mulder p963 | doi:10.1038/nrd3614 Full Text | PDF
Advertisement
Miami 2012 Winter Symposium: Nanotechnology in Biomedicine February 26-29, 2012 • Miami, FL, USA The 45th Miami Winter Symposium will bring together leaders in the field to discuss breakthroughs in new nanomaterials and the challenges in translating these materials into products for the clinic and laboratory. For more information and to register, visit: www.nature.com/natureconferences/miami/ Abstract Submission Deadline EXTENDED to November 30, 2011
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.